Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease-Driving Inflammation While Promoting Regulatory B...

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Multiple sclerosis (MS) treatments often cause broad immunosuppression, raising safety concerns.
• There is a need for therapies that selectively target pathogenic immune cells while preserving essential functions.
• Bruton tyrosine kinase (BTK) is a key signaling molecule in B-cell and myeloid cell activation.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting Bruton tyrosine kinase (BTK).
• To evaluate the effects of the BTK inhibitor evobrutinib in experimental models of central nervous system (CNS) demyelination.
• To assess the impact of BTK inhibition on B-cell and myeloid cell function.

Main Methods:

• Evobrutinib's effects were tested in various in vivo CNS demyelination models.
• Phenotypical and functional alterations in immune cells were analyzed using flow cytometry.
• In vitro studies examined myeloid cell responses to BTK inhibition under Fc receptor-mediated stimulation.

Main Results:

• Evobrutinib promoted regulatory B-cell properties in healthy and demyelination models.
• BTK inhibition limited pro-inflammatory B-cell differentiation and supported regulatory functions.
• BTK inhibition attenuated myeloid cell activation, suppressed pro-inflammatory cytokines, and reduced antigen presentation.

Conclusions:

• BTK inhibition presents a selective and sustainable immunomodulatory strategy for chronic CNS inflammation.
• Unlike broad immunosuppressants, BTK inhibition preserves essential B-cell functions while targeting pathogenic responses.
• This approach holds potential for broad application, possibly in combination with other anti-inflammatory agents.